Insider Purchases: Inside the Buy
Tag: CFO Insider Buying
Simmons Bank: Insider Buys, 116 Years of Dividends, and a Footlong Public Offering
Simmons Bank has paid dividends for over a century—and insiders just went on a buying spree. 📉 Stock’s dipped, 🔍 valuation isn’t screaming cheap, but with improving net income and institutional support, SFNC might be worth a second look. If not exciting, at least it’s… dependable?
Helen of Troy (HELE) — Insider Buys, CFOs Turned CEOs, and a Falling Knife You Might Want to Catch (Carefully)
The CEO and CFO of Helen of Troy just bought shares as the stock plunges 90%. Are we looking at a tragic tale, or a comeback for the ages? We dig into the numbers, leadership shuffle, and Wall Street signals—with humor and historical flair.
Xerox Holdings: This Company Still Exists—To Be or Not To Be... In Your Portfolio?
Xerox might feel like yesterday’s news, but insiders and institutions clearly disagree. With executives loading up on shares and a reinvention strategy underway, this classic name could be more than a relic—it might just be your next contrarian play. 📠💥
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?